[{"uuid": "9982b779-f2ec-3c2c-be00-453372adc98a", "title": "Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex", "publisher": "TipRanks", "link": "https://finance.yahoo.com/news/fortress-biotech-announces-first-patient-134113078.html", "providerPublishTime": 1738071673, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/mZDcjNmmKhClNQkla1p5GA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa", "width": 192, "height": 192, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/JR57pJ12h3k1wjWsvT64Rw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FBIO", "FBIOP"]}, {"uuid": "ad7b9062-a058-30cd-be26-663ba4c7355c", "title": "Fortress doses first subject in Phase II CMV vaccine trial", "publisher": "Clinical Trials Arena", "link": "https://finance.yahoo.com/m/ad7b9062-a058-30cd-be26-663ba4c7355c/fortress-doses-first-subject.html", "providerPublishTime": 1738066885, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/hFcLT4..peCiZ3q25wN_PA--~B/aD05NjA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/0871b1f171d1be7c60698f7544ca2a09", "width": 1440, "height": 960, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/nY4Qeb1n1IHbHQSPTCj5xA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/0871b1f171d1be7c60698f7544ca2a09", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FBIO", "FBIOP"]}, {"uuid": "dfe8a215-6c72-3be1-8127-c315e2732468", "title": "Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/fortress-biotech-announces-first-patient-133000690.html", "providerPublishTime": 1737984600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/AEcy1bQEW49pdl430uN.3Q--~B/aD0zNDY7dz00NTU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b3f034180af5ad6bdba856b546d8c273", "width": 455, "height": 346, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/4RQcbR9QX64yzB54KYn0iA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b3f034180af5ad6bdba856b546d8c273", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FBIO", "FBIOP"]}, {"uuid": "74e5411e-8db7-305e-b68f-545ba7f910c3", "title": "Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi\u2122 (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/journey-medical-corporation-host-conference-133000578.html", "providerPublishTime": 1737639000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/9s0f0g_cM1tb2KB42Hcn1g--~B/aD05MTt3PTIxMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/f4f8abb1712715fc7e1e013da4b75ecc", "width": 210, "height": 91, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/SJDk0_icHtQMjADHDQwk4A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f4f8abb1712715fc7e1e013da4b75ecc", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DERM", "FBIO", "FBIOP"]}, {"uuid": "1dd5b76a-4f51-39cb-9af4-d4b54b798b17", "title": "Mustang Bio Announces Reverse Stock Split", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/mustang-bio-announces-reverse-stock-130000004.html", "providerPublishTime": 1736859600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/.VQhMyzFQDzQvaod3cceuw--~B/aD0xMTY7dz0xNjY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/00aaf9fc3df99c9b14bc3fecfe879c18", "width": 166, "height": 116, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/_OsgH0Gpi_9AcUM2_oLFdQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/00aaf9fc3df99c9b14bc3fecfe879c18", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["MBIO", "FBIO", "FBIOP"]}, {"uuid": "f223c64a-5a8b-3bb0-ba50-cb0a9b0eb1de", "title": "Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/fortress-biotech-cyprium-therapeutics-announce-130000782.html", "providerPublishTime": 1736168400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/AEcy1bQEW49pdl430uN.3Q--~B/aD0zNDY7dz00NTU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b3f034180af5ad6bdba856b546d8c273", "width": 455, "height": 346, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/4RQcbR9QX64yzB54KYn0iA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b3f034180af5ad6bdba856b546d8c273", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FBIO", "FBIOP"]}, {"uuid": "521e8c7b-208f-3a1b-8c7e-3721182aec29", "title": "Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/sentynl-therapeutics-announces-u-fda-130000194.html", "providerPublishTime": 1736168400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/nyOgZTre3FNgkABE0HnZDQ--~B/aD03NDt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/fd013e70acfdc4ac3eed9836b2a93ef0", "width": 400, "height": 74, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/5HxOBkVLQ.AF5ee36j2x9w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/fd013e70acfdc4ac3eed9836b2a93ef0", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FBIO", "FBIOP"]}, {"uuid": "aaaec66b-74c6-332b-9ae2-01b6fa75862a", "title": "FDA accepts Sentynl\u2019s Menkes disease therapy NDA for priority review", "publisher": "Pharmaceutical Technology", "link": "https://finance.yahoo.com/m/aaaec66b-74c6-332b-9ae2-01b6fa75862a/fda-accepts-sentynl%E2%80%99s-menkes.html", "providerPublishTime": 1736251154, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/DeDtaxaqebdxt6YpV7AdHw--~B/aD05NjA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/8dad9e62741da795cc66d2db119125b0", "width": 1440, "height": 960, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/puU3WFj8cWEcJ_cHAcW9_A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/8dad9e62741da795cc66d2db119125b0", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FBIO"]}, {"uuid": "ebace584-8c23-3243-b046-e3950e60eaa1", "title": "Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/fortress-biotech-reports-third-quarter-211000592.html", "providerPublishTime": 1731618600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/AEcy1bQEW49pdl430uN.3Q--~B/aD0zNDY7dz00NTU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b3f034180af5ad6bdba856b546d8c273", "width": 455, "height": 346, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/4RQcbR9QX64yzB54KYn0iA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b3f034180af5ad6bdba856b546d8c273", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FBIO", "FBIOP"]}, {"uuid": "86fa0840-10db-38e0-8f4d-b2c5b7827086", "title": "Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/fortress-biotech-third-quarter-2024-122530541.html", "providerPublishTime": 1731846330, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c", "width": 945, "height": 636, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/NamfX5LEtyScIu4YmRG2hg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FBIO", "FBIOP"]}, {"uuid": "78335484-b4d6-3d89-9823-e104ab9d5c67", "title": "Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT\u2122\u00a0(cosibelimab-ipdl)", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/checkpoint-therapeutics-announces-fda-approval-231500549.html", "providerPublishTime": 1734131700, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/yxfPFV.CffuFdkzENPgdgQ--~B/aD04NTg7dz0yMTEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/33d6469a0dff749484186c50b38ae4a2", "width": 2112, "height": 858, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/JecFprgp_Mp3ufKabUsdUA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/33d6469a0dff749484186c50b38ae4a2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FBIO", "FBIOP", "CKPT"]}, {"uuid": "4bc80f52-d582-3966-b403-e44db5b10895", "title": "Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/journey-medical-corporation-reports-third-210100293.html", "providerPublishTime": 1731445260, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/9s0f0g_cM1tb2KB42Hcn1g--~B/aD05MTt3PTIxMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/f4f8abb1712715fc7e1e013da4b75ecc", "width": 210, "height": 91, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/SJDk0_icHtQMjADHDQwk4A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f4f8abb1712715fc7e1e013da4b75ecc", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FBIO", "FBIOP", "DERM"]}, {"uuid": "cc4d1af4-0f20-38a8-94f1-47dec18e89da", "title": "Fortress Biotech: Q3 Earnings Snapshot", "publisher": "Associated Press Finance", "link": "https://finance.yahoo.com/news/fortress-biotech-q3-earnings-snapshot-220403702.html", "providerPublishTime": 1731621843, "type": "STORY", "relatedTickers": ["FBIO"]}, {"uuid": "6ef8d788-35c6-3dbb-bdd1-fb2fffd1bfe9", "title": "Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/checkpoint-therapeutics-reports-third-quarter-213000203.html", "providerPublishTime": 1731447000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/yxfPFV.CffuFdkzENPgdgQ--~B/aD04NTg7dz0yMTEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/33d6469a0dff749484186c50b38ae4a2", "width": 2112, "height": 858, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/JecFprgp_Mp3ufKabUsdUA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/33d6469a0dff749484186c50b38ae4a2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["FBIO", "FBIOP", "CKPT"]}, {"uuid": "50d042b9-ee1f-33d5-b592-731dca7ac543", "title": "Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/avenue-therapeutics-reports-third-quarter-210500462.html", "providerPublishTime": 1731618300, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/OI_YNA8UlVdfTIntWDs53g--~B/aD0xMTY3O3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4911f3f6b9732d5c8fc6eb86ddea6f77", "width": 2000, "height": 1167, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/PEYfovLfKQsh6t_eVfPgdw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/4911f3f6b9732d5c8fc6eb86ddea6f77", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ATXI", "FBIO", "FBIOP"]}, {"uuid": "efed3367-4bbb-3a96-ba43-493850114226", "title": "Mustang Bio Receives Positive Listing Determination from Nasdaq", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/mustang-bio-receives-positive-listing-133000142.html", "providerPublishTime": 1731418200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/.VQhMyzFQDzQvaod3cceuw--~B/aD0xMTY7dz0xNjY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/00aaf9fc3df99c9b14bc3fecfe879c18", "width": 166, "height": 116, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/_OsgH0Gpi_9AcUM2_oLFdQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/00aaf9fc3df99c9b14bc3fecfe879c18", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["MBIO", "FBIO", "FBIOP"]}, {"uuid": "fcc3833c-2705-3700-996a-13f6d213bd48", "title": "Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/mustang-bio-granted-orphan-drug-133000183.html", "providerPublishTime": 1730986200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/.VQhMyzFQDzQvaod3cceuw--~B/aD0xMTY7dz0xNjY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/00aaf9fc3df99c9b14bc3fecfe879c18", "width": 166, "height": 116, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/_OsgH0Gpi_9AcUM2_oLFdQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/00aaf9fc3df99c9b14bc3fecfe879c18", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["MBIO", "FBIO", "FBIOP"]}]